Long-term anakinra therapy in Schnitzler syndrome: real-world evidence on remission of neutrophilic dermatitis and systemic inflammation, safety, biomarker insights and dose optimization

Mariusz Sikora, Marcin Ziętkiewicz, Karina Jahnz-Różyk, Ewa Więsik-Szewczyk

Open source

DOI
10.3389/fimmu.2026.1830866
Published
2026-05-04
Container
Frontiers in Immunology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1830866,
  title = {Long-term anakinra therapy in Schnitzler syndrome: real-world evidence on remission of neutrophilic dermatitis and systemic inflammation, safety, biomarker insights and dose optimization},
  author = {Mariusz Sikora and Marcin Ziętkiewicz and Karina Jahnz-Różyk and Ewa Więsik-Szewczyk},
  year = {2026},
  journal = {Frontiers in Immunology},
  doi = {10.3389/fimmu.2026.1830866},
  url = {https://doi.org/10.3389/fimmu.2026.1830866}
}

RIS

TY  - JOUR
TI  - Long-term anakinra therapy in Schnitzler syndrome: real-world evidence on remission of neutrophilic dermatitis and systemic inflammation, safety, biomarker insights and dose optimization
AU  - Mariusz Sikora
AU  - Marcin Ziętkiewicz
AU  - Karina Jahnz-Różyk
AU  - Ewa Więsik-Szewczyk
PY  - 2026
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1830866
UR  - https://doi.org/10.3389/fimmu.2026.1830866
ER  - 

APA

Sikora, M., Ziętkiewicz, M., Jahnz-Różyk, K., & Więsik-Szewczyk, E. (2026). Long-term anakinra therapy in Schnitzler syndrome: real-world evidence on remission of neutrophilic dermatitis and systemic inflammation, safety, biomarker insights and dose optimization. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1830866

Source records